RVMD Pulls Back as Street Conviction Stays Strong

Short positioning tells a fairly calm story beneath the headline ticker move. Short interest has fallen roughly 7% on the week to 5% of the free float, the direction of travel is clearly toward covering rather than building. The cost to borrow has crept up 14% on the week to 0.52%, its highest level in the recent window, but the absolute level remains very low. Availability in the lending market is exceptionally loose at over 4,000% of outstanding short interest, meaning there are roughly 42 shares available to borrow for every one currently lent out. The ORTEX short score is a middling 42.5, well within neutral territory, and has been drifting gently lower over the past two weeks. Nothing in the borrow market points to a contested short position.

Options positioning is similarly uneventful. The put/call ratio has settled near 0.85, almost exactly in line with its 20-day average of 0.84, and the z-score of 0.16 is essentially flat. That reading is nowhere near the 52-week high of 1.80, which would signal genuine fear, nor near the low of 0.16, which would indicate speculative excess. With Q3 results due in 29 days, options traders do not appear to be pricing a sharp binary event, at least not yet.

Institutional ownership adds an important layer of texture. BlackRock added 2.5 million shares in the quarter to September 30, pushing its stake to 6.4% of shares outstanding. Fidelity (FMR) added 3.5 million shares in the same period to reach 5.6%. Capital Research entered the register with a full 4 million-share position. On the activist register, all disclosed holders are on 13G (passive) filings, none on 13D, so there is no activism angle here. Stakes are as-last-disclosed around the 5% threshold, and holders dropping below that level may exit without a further filing. The insider picture is routine. All recent Form 4 activity from the Chief Development Officer and General Counsel was executed under 10b5-1 pre-arranged plans, compensation-related option exercises followed by open-market sales at around $200 to $207. The 90-day net position for insiders runs to roughly negative 181,000 shares, but the planned nature of every transaction strips most of the signal from that figure.

Retail attention is running well above its own recent baseline. The ORTEX alt data layer flags Wikipedia page views for RVMD at a z-score of 3.9 against the company's own trailing 90-day history, a reading from late September that reflects the surge of attention following the daraxonrasib approval. No alt data dataset has been shown to lead RVMD's reported financial figures, so this is colour rather than a directional read on the next print.

The next reporting date is November 5. What to watch between now and then is whether the Street's near-consensus buy thesis begins to translate into commercial prescription data for daraxonrasib, and whether the short covering trend continues or reverses as bears assess the pace of the commercial ramp against the high valuation implied by a price-to-book multiple that has eased slightly but remains above 28 times.